Equities

Scholar Rock Holding Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Scholar Rock Holding Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)35.99
  • Today's Change0.44 / 1.24%
  • Shares traded200.00
  • 1 Year change+363.19%
  • Beta0.4971
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

  • Revenue in USD (TTM)0.00
  • Net income in USD-264.16m
  • Incorporated2017
  • Employees196.00
  • Location
    Scholar Rock Holding Corp301 BINNEY STREET, 3RD FLOORCAMBRIDGE 02142United StatesUSA
  • Phone+1 (857) 259-3860
  • Fax+1 (302) 655-5049
  • Websitehttps://scholarrock.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xenon Pharmaceuticals Inc7.50m-251.45m2.55bn316.00--3.62--340.29-3.22-3.220.09609.190.009--1.5823,734.18-30.25-22.00-31.27-22.93-----3,352.61-1,082.36----0.00-------28.48--19.92--
Crinetics Pharmaceuticals Inc760.00k-328.25m2.79bn437.00--2.22--3,673.25-3.82-3.820.008813.410.0007--0.09631,739.13-28.06-36.96-29.43-39.20-----43,191.05-7,785.98----0.00---74.11-2.73-39.10--50.86--
Apogee Therapeutics Inc0.00-205.39m2.83bn196.00--4.11-----3.59-3.590.0011.550.00----0.00-26.71---27.69--------------0.00-------116.88------
Immunovant Inc0.00-413.84m2.90bn362.00--4.08-----2.74-2.740.004.160.00----0.00-57.37-47.00-62.46-51.13------------0.00-------59.58--89.57--
Metsera Inc0.00-265.84m3.09bn74.00--6.11-----2.87-2.870.004.82------0.00--------------------0.0165-------343.01------
MoonLake Immunotherapeutics0.00-145.21m3.14bn100.00--7.61-----2.30-2.300.006.420.00----0.00-27.49---28.77-------------9,486.420.1504-------230.31------
Kymera Therapeutics Inc58.89m-240.88m3.14bn208.00--3.71--53.36-3.10-3.100.76112.070.0659--5.35313,218.10-26.97-23.82-28.82-27.88-----409.07-240.35----0.0044---40.1174.20-52.32--89.02--
Protagonist Therapeutics Inc207.80m56.19m3.16bn124.0067.294.5954.0815.230.75860.75863.2911.130.303--1.271,649,214.008.19-7.118.67-7.93----27.04-21.29----0.00--624.06351.71448.54--6.98--
Viking Therapeutics Inc0.00-128.24m3.17bn45.00--3.74-----1.15-1.150.007.540.00----0.00-13.98-22.44-14.39-23.61------------0.00-------28.02------
Scholar Rock Holding Corp0.00-264.16m3.42bn196.00--10.93-----2.54-2.540.003.290.00----0.00-78.29-45.06-88.09-51.62-------1,134.62----0.1374-------48.56---49.93--
ACADIA Pharmaceuticals Inc996.28m228.88m3.51bn653.0015.274.5814.483.521.371.375.974.581.001.879.941,525,701.0023.03-13.1533.80-16.7492.0494.4922.97-16.002.80--0.00--31.8523.08469.50---14.26--
Arcellx Inc76.81m-162.42m3.70bn163.00--8.87--48.18-2.99-2.991.427.570.1076----471,220.80-22.75-27.24-26.90-32.13-----211.46-212.50----0.00---2.16---51.86--28.52--
Akero Therapeutics Inc0.00-269.44m4.13bn69.00--3.81-----3.75-3.750.0013.600.00----0.00-26.06-36.86-27.01-38.94------------0.0317-------66.09------
Krystal Biotech Inc333.45m123.96m4.13bn275.0034.494.2031.6412.404.154.1511.1734.070.3461.114.451,212,535.0012.86-4.8113.77-5.0793.20--37.18-41.519.27--0.00--473.02--715.58---7.91--
Cytokinetics, Inc.19.22m-615.26m4.14bn498.00------215.39-5.31-5.310.1658-2.230.0186--13.5138,590.36-59.38-45.50-67.48-50.38-----3,201.47-748.37---16.681.68--145.34-7.22-12.03--8.32--
Data as of Jul 03 2025. Currency figures normalised to Scholar Rock Holding Corp's reporting currency: US Dollar USD

Institutional shareholders

54.00%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 202513.75m14.68%
T. Rowe Price Associates, Inc. (IM)as of 31 Mar 20258.81m9.41%
BlackRock Fund Advisorsas of 31 Mar 20256.03m6.44%
The Vanguard Group, Inc.as of 31 Mar 20254.67m4.99%
Redmile Group LLCas of 31 Mar 20254.40m4.70%
SSgA Funds Management, Inc.as of 31 Mar 20253.13m3.35%
Eventide Asset Management LLCas of 31 Mar 20252.66m2.84%
Polar Capital LLPas of 31 Mar 20252.58m2.76%
Bellevue Asset Management AGas of 31 Mar 20252.51m2.68%
Adage Capital Management LPas of 31 Mar 20252.02m2.16%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.